Kiyoshi Hasegawa

Protocol of the STRIDE-X study: a multicenter, single-arm trial of single tremelimumab regular interval durvalumab followed by hepatectomy for initially unresectable hepatocellular carcinoma

Abstract Background Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related death. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab has recently emerged as a first-line the...